Celldex Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Celldex Therapeutics kazanç ve gelirin sırasıyla yıllık 39.5% ve 69.8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 43.7% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -56.3% olacağı tahmin edilmektedir.

Anahtar bilgiler

39.5%

Kazanç büyüme oranı

43.74%

EPS büyüme oranı

Biotechs kazanç büyümesi	25.3%
Gelir büyüme oranı	69.8%
Gelecekteki özkaynak getirisi	-56.26%
Analist kapsamı	Good
Son güncelleme	08 May 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Analiz Makalesi • May 06

Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Seeking Alpha • Apr 22

Celldex Therapeutics: Strong Pipeline But Uncertainties Remain

Summary We initiate a Hold rating for Celldex Therapeutics due to uncertainties surrounding barzolvolimab's mid-2025 data readouts and potential market positioning challenges. Barzolvolimab's Phase 3 trials target chronic spontaneous urticaria, chronic inducible urticaria, eosinophilic esophagitis, prurigo nodularis, and atopic dermatitis, with mixed competitive prospects. Celldex’s cash runway extends into 2027, but potential delays or hurdles could necessitate earlier fundraising, exerting downward pressure on valuation. Investment risks include trial failures, commercial uptake challenges, resource-intensive commercialization, potential side effects, and broader macroeconomic factors affecting funding and share price. Read the full article on Seeking Alpha

Analiz Makalesi • Jan 28

Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analiz Makalesi • Jun 07

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

Key Insights Celldex Therapeutics to hold its Annual General Meeting on 13th of June Total pay for CEO Anthony Marucci...

Analiz Makalesi • Jun 05

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • Jul 07

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analiz Makalesi • Apr 21

An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Key Insights Celldex Therapeutics' estimated fair value is US$54.52 based on 2 Stage Free Cash Flow to Equity Celldex...

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:CLDX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2028	142	-280	-196	-152	9
12/31/2027	11	-373	-281	-296	9
12/31/2026	2	-334	-281	-273	9
3/31/2026	1	-284	-226	-222	N/A
12/31/2025	2	-259	-214	-211	N/A
9/30/2025	3	-225	-182	-179	N/A
6/30/2025	6	-200	-188	-186	N/A
3/31/2025	8	-179	-173	-172	N/A
12/31/2024	7	-158	-160	-158	N/A
9/30/2024	10	-154	-160	-158	N/A
6/30/2024	8	-150	-123	-121	N/A
3/31/2024	6	-145	-121	-119	N/A
12/31/2023	7	-141	-109	-107	N/A
9/30/2023	4	-125	-98	-97	N/A
6/30/2023	3	-113	-114	-113	N/A
3/31/2023	3	-119	-110	-108	N/A
12/31/2022	2	-112	-106	-104	N/A
9/30/2022	1	-106	-98	-96	N/A
6/30/2022	1	-100	-79	-78	N/A
3/31/2022	4	-77	-69	-67	N/A
12/31/2021	5	-71	-62	-61	N/A
9/30/2021	8	-72	-53	-52	N/A
6/30/2021	9	-66	-48	-47	N/A
3/31/2021	5	-64	-48	-46	N/A
12/31/2020	7	-60	-42	-40	N/A
9/30/2020	5	-48	-48	-46	N/A
6/30/2020	4	-46	-47	-45	N/A
3/31/2020	5	-46	-46	-45	N/A
12/31/2019	4	-51	N/A	-46	N/A
9/30/2019	4	-50	N/A	-51	N/A
6/30/2019	5	-46	N/A	-54	N/A
3/31/2019	7	-50	N/A	-60	N/A
12/31/2018	10	-151	N/A	-75	N/A
9/30/2018	11	-146	N/A	-79	N/A
6/30/2018	14	-165	N/A	-89	N/A
3/31/2018	15	-177	N/A	-93	N/A
12/31/2017	13	-93	N/A	-100	N/A
9/30/2017	11	-121	N/A	-101	N/A
6/30/2017	9	-125	N/A	-100	N/A
3/31/2017	7	-128	N/A	-113	N/A
12/31/2016	7	-129	N/A	-113	N/A
9/30/2016	7	-129	N/A	-106	N/A
6/30/2016	6	-131	N/A	-110	N/A
3/31/2016	6	-132	N/A	-101	N/A
12/31/2015	5	-127	N/A	-99	N/A
9/30/2015	5	-126	N/A	-107	N/A
6/30/2015	5	-122	N/A	-106	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CLDX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: CLDX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: CLDX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: CLDX şirketinin gelirinin (yıllık 69.8% ) US pazarından (yıllık 11.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: CLDX şirketinin gelirinin (yıllık 69.8% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CLDX 3 yıl içinde kârsız olması bekleniyor.

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/12 02:34
Gün Sonu Hisse Fiyatı	2026/05/12 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Celldex Therapeutics, Inc. 22 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Etzer Darout	Barclays
Edward Nash	Canaccord Genuity
Kristen Kluska	Cantor Fitzgerald & Co.

Celldex Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates fall by 19%

Price target decreased by 7.9% to US$53.85

Consensus revenue estimates fall by 18%

Price target decreased by 11% to US$57.58

Consensus revenue estimates increase by 15%, EPS downgraded

Consensus revenue estimates increase by 65%

Recent updates

New major risk - Revenue size

First quarter 2026 earnings: EPS and revenues miss analyst expectations

Celldex Advances Barzolvolimab Trials With Strong Cash Position After Q1 Earnings Miss

Celldex Therapeutics, Inc., Annual General Meeting, Jun 25, 2026

New minor risk - Shareholder dilution

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.005 million.

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering.

Celldex Therapeutics, Inc. Presents Positive Data From Phase 2 Chronic Spontaneous Urticaria And Phase 2 Cold Urticaria And Symptomatic Dermographism Studies Demonstrating Rapid, Profound And Durable Improvements In Patient Quality Of Life At AAD 2026

Celldex Presents Positive Data Demonstrating Barzolvolimab Ret Treatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (Coldu) and Symptomatic Dermographism (Sd) Further Demonstrating First Exposure in Patients with Barzolvolimab

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (Csu) and Phase 2 Cold Urticaria (Coldu) and Symptomatic Dermographism (Sd) Studies Further Demonstrating First-In-Class and Best-Disease

Full year 2025 earnings: EPS and revenues miss analyst expectations

Celldex Completes Enrollment in Global Phase 3 Studies (Embarq-Csu1 and Embarq-Csu2) of Barzolvolimab in Chronic Spontaneous Urticaria

Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism

Chief Commercial Officer & Senior VP exercised options and sold US$490k worth of stock

Consensus revenue estimates fall by 19%

Third quarter 2025 earnings released: US$1.01 loss per share (vs US$0.64 loss in 3Q 2024)

Celldex Therapeutics, Inc. Announces Executive Changes

Celldex Presents Additional Positive Data Demonstrating Barzolvolimab's Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria Study

Celldex Therapeutics, Inc. Announces Initial Positive Results from Phase 1 Trial of CDX-622

Price target decreased by 7.9% to US$53.85

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Celldex Therapeutics, Inc.(NasdaqCM:CLDX) dropped from Russell 2500 Growth Index

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

Celldex Therapeutics Announces Election of Denice Torres to Its Board of Directors

Consensus revenue estimates fall by 18%

Price target decreased by 11% to US$57.58

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in This Difficult to Treat Disease

Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation

Celldex Therapeutics, Inc., Annual General Meeting, Jun 05, 2025

Celldex Therapeutics: Strong Pipeline But Uncertainties Remain

Now 20% overvalued

Consensus revenue estimates increase by 15%, EPS downgraded

Celldex Therapeutics, Inc. Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life At Aaaai 2025

Full year 2024 earnings: EPS in line with analyst expectations despite revenue beat

Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation

Now 25% undervalued after recent price drop

New major risk - Revenue and earnings growth

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Founder recently bought US$308k worth of stock

Consensus revenue estimates increase by 65%

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Celldex Therapeutics, Inc. Announces Positive Results from its Phase 2 Clinical Trial of Barzolvolimab

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 65%, EPS downgraded

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Celldex Therapeutics, Inc. Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Price target decreased by 7.6% to US$65.38

Senior VP & Chief Medical Officer recently sold US$1.6m worth of stock

Chief Commercial Officer & Senior VP notifies of intention to sell stock

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria At Eaaci 2024

Senior VP recently sold US$341k worth of stock

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

Consensus revenue estimates decrease by 20%, EPS upgraded

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Celldex Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Price target increased by 9.7% to US$69.43

Celldex Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 26, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind